Scholarlink

<p>Combining immunotherapy with chemoradiation is effective in locally advanced cervical cancer. However, the impact of induction combination immunotherapy on immune modulation and treatment response is poorly understood. In this phase II trial (NCT04256213), 40 females with locally advanced cervical carcinoma received one cycle of nivolumab-plus-ipilimumab immunotherapy before standard chemoradiation, followed by maintenance nivolumab. We show, using multiplex-immunofluorescence tissue imaging, a&#xa0;significantly increased CD8<sup>+</sup>/FOXP3<sup>+</sup> cell ratio (primary endpoint; increase of 0.87 cells/mm², <i>P</i> = 0.0164) and proliferative CD8<sup>+</sup> T-cell density after one cycle of combination immunotherapy. HOT score (27-gene-based signature identifying immunologically active tumors) also increased significantly (exploratory analysis; 0.17, <i>P</i> &lt; 0.0001). Objective response rates (secondary endpoint) were 13% immediately after combination immunotherapy, 98% (65% complete response) after chemoradiation, and 90% at treatment completion. High HOT score at baseline and immune changes induced by combination immunotherapy were associated with complete response at treatment completion. Induction immunotherapy may prime tumors for improved response to standard therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Neoadjuvant immune checkpoint blockade before chemoradiation for cervical squamous carcinoma (GINECO window-of-opportunity COLIBRI study): a phase II trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月5日

查看全文
  • Isabelle Ray-Coquard,
  • Marie-Christine Kaminsky-Forrett,
  • Ryotaro Ohkuma,
  • Aymeric de Montfort,
  • Florence Joly,
  • Isabelle Treilleux,
  • Sarah Ghamry-Barrin,
  • Diana Bello-Roufai,
  • Pierre Saintigny,
  • Antoine Angelergues,
  • Lucas Michon,
  • Anne-Claire Hardy-Bessard,
  • Valéry Attignon,
  • Jessie Auclair,
  • Gabriel Chemin,
  • Alexandra Lainé,
  • Hélène Péré,
  • David Veyer,
  • Aude-Marie Savoye,
  • Justine Berthet,
  • Christophe Caux,
  • Fabrice Lecuru,
  • Bertrand Dubois,
  • Sarah Bétrian

摘要

Combining immunotherapy with chemoradiation is effective in locally advanced cervical cancer. However, the impact of induction combination immunotherapy on immune modulation and treatment response is poorly understood. In this phase II trial (NCT04256213), 40 females with locally advanced cervical carcinoma received one cycle of nivolumab-plus-ipilimumab immunotherapy before standard chemoradiation, followed by maintenance nivolumab. We show, using multiplex-immunofluorescence tissue imaging, a significantly increased CD8+/FOXP3+ cell ratio (primary endpoint; increase of 0.87 cells/mm², P = 0.0164) and proliferative CD8+ T-cell density after one cycle of combination immunotherapy. HOT score (27-gene-based signature identifying immunologically active tumors) also increased significantly (exploratory analysis; 0.17, P < 0.0001). Objective response rates (secondary endpoint) were 13% immediately after combination immunotherapy, 98% (65% complete response) after chemoradiation, and 90% at treatment completion. High HOT score at baseline and immune changes induced by combination immunotherapy were associated with complete response at treatment completion. Induction immunotherapy may prime tumors for improved response to standard therapy.